FiercePharma

Pharma’s go-to destination for news & trends shaping approved drugs. Delivering news, revealing insights straight to your inbox.

[FiercePharma @FiercePharma]

Nature Medicine has pulled a controversial paper tying lung cancer survival to PD-1 treatment timing
https://t.co/JxAbOc6gI8

[Angus Liu @Angus_Fierce]

After a 4-month investigation, Nature has decided to retract viral PD-1 study that tied lung cancer survival to treatment timing https://t.co/nnVSmWU1Pf

[FiercePharma @FiercePharma]

The world’s first solid tumor approval for a CAR-T therapy has arrived in China
https://t.co/LnWbzecDEV

[FiercePharma @FiercePharma]

After leaving his mark on the company through a series of high-profile M&A deals, Pfizer’s CFO Dave Denton is staging an exit
https://t.co/KGPYfxTTyc

[FiercePharma @FiercePharma]

An dealmaking surge has brought the biopharma ecosystem ‘back to full health,’ PwC argues in a new report
https://t.co/nqBtuWHdGr

[FiercePharma @FiercePharma]

Regulatory tracker: Novo to soon seek China approval for Wegovy pill, CEO says https://t.co/fWS6b9pBDb

[FiercePharma @FiercePharma]

After FDA sign-off, Colorado's drug import plan faces tough road ahead https://t.co/kCwbzg4N4j

[FiercePharma @FiercePharma]

With pharma and life sciences deal values surpassing $65 billion in Q1, marking the strongest quarter in the industry since 2020, analysts from PwC have declared that the “biopharma ecosystem is back to full health.” https://t.co/nqBtuWHdGr

[FiercePharma @FiercePharma]

Fierce’s annual ranking of the best-paid CEOs in Big Pharma has arrived
https://t.co/rQlfH5vu4j

[FiercePharma @FiercePharma]

With a new FDA nod for Welireg, Merck’s post-Keytruda future is looking a bit brighter
https://t.co/Y2M9mXJZvj

[FierceBiotech @FierceBiotech]

Chutes & Ladders—Perrigo CEO ousted over ‘personal conduct’ https://t.co/3wgFaQT3Uc

[FiercePharma @FiercePharma]

‘Not simply saving cost’: Inside Astellas CEO’s 5-year strategy to counter Xtandi’s patent cliff https://t.co/Roo0T1EVx1

[FierceBiotech @FierceBiotech]

Today on The Top Line, Fierce EIC @AylaEllison sits down with Ipsen's R&D chief to discuss the biopharma's approach to partnerships, its strategy for expanding the pipeline, and where its focus is in 2026. https://t.co/2TVNrouM2Q

[FierceBiotech @FierceBiotech]

‘I’m a lot more optimistic today’: Mike Doustdar tells Fierce about pivotal first year as Novo Nordisk CEO https://t.co/xgt47tl9jD

[FiercePharma @FiercePharma]

‘I’m a lot more optimistic today’: Mike Doustdar tells Fierce about pivotal first year as Novo Nordisk CEO https://t.co/mSp6JCqAPr

[FiercePharma @FiercePharma]

Pfizer scores FDA pediatric expansion for hemophilia treatment Hympavzi https://t.co/j2OF0FhfCg

[FiercePharma @FiercePharma]

‘Law & Order’ star Mariska Hargitay teams up with BMS to investigate multiple myeloma research in awareness campaign https://t.co/NgCYrj4WuT

[FiercePharma @FiercePharma]

With ADA in the books, analyst says Lilly is ‘widening its lead’ in the obesity race https://t.co/H73GAMWlm9

[FiercePharma @FiercePharma]

Lilly posts oral semaglutide-topping data as Foundayo speeds toward 2nd potential nod in diabetes https://t.co/RcZDJHkaXu

[FiercePharma @FiercePharma]

The Oral GLP-1 Tracker: Oral Wegovy hits 3M prescription milestone https://t.co/sHrXXXhEpk